Precision Antibacterial Therapies

About Locus Biosciences

Locus Biosciences is a private, clinical-stage biotech leveraging a sophisticated AI and robotics platform, LOCUS, to industrialize the development of engineered bacteriophage therapies. The company's most advanced asset, LBP-EC01 for E. coli infections, has reported positive Phase 2 results, positioning it as a leader in the precision antibacterial space. Backed by significant NIH funding and strategic partnerships, Locus is expanding its pipeline to address antibiotic-resistant infections across multiple therapeutic areas while operating its own cGMP manufacturing facility.

Therapeutic Areas